Sentry Investment Management LLC Sells 15,131 Shares of Pfizer Inc. (NYSE:PFE)

Sentry Investment Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 46.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,650 shares of the biopharmaceutical company’s stock after selling 15,131 shares during the period. Sentry Investment Management LLC’s holdings in Pfizer were worth $508,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. RB Capital Management LLC boosted its position in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its position in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank increased its holdings in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. Ergoteles LLC grew its position in Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp grew its position in Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.1 %

PFE stock opened at $25.88 on Tuesday. Pfizer Inc. has a one year low of $25.61 and a one year high of $41.33. The company has a fifty day moving average of $27.27 and a 200-day moving average of $28.84. The stock has a market capitalization of $146.55 billion, a PE ratio of 71.94, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.